Last reviewed · How we verify
NCT03759704: HPMSS
Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)
trial testing Hyperpolarized 13CPyruvate in Sarcoma, Soft Tissue. Withdrawn.
26 August 2021
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 January 2019 |
| Primary completion | 26 August 2021 |
| Estimated completion | 26 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperpolarized 13CPyruvate — full drug profile →
Conditions studied
- Sarcoma, Soft Tissue — all drugs for Sarcoma, Soft Tissue →
Sponsor
University of Texas Southwestern Medical Center
Who can join
Adults 18 to 100, any sex, with Sarcoma, Soft Tissue. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators will determine whether MRSI using hyperpolarized \[1-13C\]pyruvate provide useful information of tumor malignancy in MRI-indeterminate cases. Metabolite maps of hyperpolarized \[1-13C\]lactate and H13CO3- produced from hyperpolarized \[1-13C\]pyruvate will be compared to the biopsy results of MRI-indeterminate patients and the 13C-maps of age-matched healthy subjects.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Metabolic response to radiation therapy in cancer.
Read GH, Bailleul J, Vlashi E, Kesarwala AH. · · 2022 · cited 25× · PMID 34961986 · DOI 10.1002/mc.23379 -
Preoperative imaging of glioblastoma patients using hyperpolarized <sup>13</sup>C pyruvate: Potential role in clinical decision making.
Chen J, Patel TR, Pinho MC, Choi C, et al · · 2021 · cited 17× · PMID 34355174 · DOI 10.1093/noajnl/vdab092
Verify or expand the search:
- PubMed search for NCT03759704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoma, Soft Tissue
Currently open trials in the same condition.
- NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
- NCT06873685 — Soft Tissue Sarcoma: Motor Performance, Robotic Rehabilitation, Nutrition, and Quality of Life · NA · recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03759704 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 4 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03759704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing